The Weekly Recap 5/8/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive regulatory approvals, launch partnerships, achieve clinical milestones, and much more on the road to LSI Asia ‘26 in Singapore (June 30 - July 2).

APEX Biologix

Welcomed LSI Alumni Jeff Cambra to its Board of Directors. Cambra brings extensive experience across the medical device and therapeutics industry, with leadership roles spanning general management, sales, marketing, and product development, along with experience supporting commercialization strategy, portfolio management, and strategic transactions.

Aqua Medical

Announced 12-month follow-up clinical data outside the U.S. for its proprietary radiofrequency vapor ablation platform, highlighting the potential of its proximal intestinal mucosal ablation procedure as a durable treatment for type 2 diabetes. Results showed up to a 2.6% reduction in HbA1c, 100% elimination of exogenous insulin in treated patients, 80% remaining insulin-free without additional medications, and a favorable safety profile for the approximately 60-minute outpatient procedure.

Calla Lily Clinical Care

Treated the first patient in the FREEDOM trial, evaluating 400mg progesterone CallavidⓇ in women with luteal phase insufficiency, a condition associated with infertility and recurrent miscarriage. Callavid is being developed as a first-in-class women’s health innovation, with the potential to become the world’s first drug-device combination product for threatened miscarriage prevention, as well as supporting luteal phase support in IVF.

Discure Technologies

Appointed Ray Baker, M.D., to its Board of Directors. Dr. Baker brings more than 30 years of experience across interventional pain, spine care, and medtech innovation, and will support the company in a fractional Chief Medical Officer capacity to support clinical, regulatory, and market-access strategy. 

E-Scopics

Received FDA clearance for new enhancements to its HepatoscopeⓇ platform, including a dedicated Spleen Exam workflow that expands the system’s utility in the non-invasive assessment of cirrhosis complications. The updated platform features optimized acquisition parameters, including adjusted vibration frequency and a spleen-specific region of interest, to improve reliability when measuring high stiffness values.

GraMedica

Announced a partnership with LovellⓇ Government Services to serve federal healthcare systems, including the Veterans Health Administration, Military Health System, and Indian Health Service. Under the partnership, Lovell will serve as GraMedica’s Service-Disabled Veteran-Owned Small Business vendor of record to help expand access to the company’s HyProCureⓇ.  

Gwen Watanabe

LSI Alumni Gwen Watanabe has co-founded Blackwell Health Partners, a new healthcare-focused private equity fund. The fund aims to unite deep healthcare and buyout expertise to accelerate the transformation of promising healthcare companies.

Interventional Systems

Announced a strategic platform partnership with ProVoyance to explore and develop integrated robotic navigation capabilities. The partnership brings together two FDA-cleared platforms, Interventional Systems’ Micromate™ miniature robot and ProVoyance’s AI-enabled preoperative planning software, into a collaboration framework to deliver seamless, end-to-end solutions for OEM partners and the surgeons and patients they serve.

Microsure

Appointed LSI Alumni Alex Joseph as its CEO and received CE mark for its MUSA-3 system. The company can now deploy the MUSA-3 system for clinical use across Europe, moving from product development to a clinical medical device business, where it aims to gather evidence and support adoption among medical centers.

MMI - Medical Microinstruments

Completed the first robotic-assisted procedure in REMIND, its U.S. IDE Study evaluating the SymaniⓇ Surgical System to perform microsurgical techniques in the region of the neck for treatment of Alzheimer’s disease. The procedure, performed using Symani, explores whether restoring lymphatic drainage pathways in the deep cervical lymph nodes may support improved clearance of harmful neurotoxins that scientific researchers believe contribute to the progression of Alzheimer’s disease. 

Noctrix Health

Entered into a definitive merger agreement to be acquired by Resmed for $340M. The company developed and manufactures Nidra, a novel non-invasive, wearable therapy to treat drug-refractory restless legs syndrome.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-5826-lsi-alumni-achievements-driving-medtech-and-healthtech-forward 

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Microbot Medical and the Endovascular Robotics Opportunity Taking Shape

In November, Microbot Medical reached a meaningful milestone in the evolution of endovascular robotics, announcing that Emory University Hospital in Atlanta has become the first hospital worldwide to use the company’s LIBERTY system for patient care. Microbot is currently operating under a limited commercial release following FDA clearance, with a broader market launch planned for April 2026 at the Society of Interventional Radiology conference. While still early, the move signals growing confidence that robotic assistance inside the vasculature is beginning to transition from concept to clinical reality. To understand why this matters, it helps to step back and examine the numbers behind the endovascular robotics market and how Microbot’s approach fits into a rapidly evolving competitive landscape. Defining the Endovascular Procedure Landscape Endovascular procedures encompass any intervention performed from within a blood vessel. In practical terms, this includes coronary, periphe...
Read more